Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE

被引:36
作者
Harris, JD
Graham, IR
Schepelmann, S
Stannard, AK
Roberts, ML
Hodges, BL
Hill, VJ
Amalfitano, A
Hassall, DG
Owen, JS
Dickson, G [1 ]
机构
[1] Univ London, Ctr Biomed Sci, Sch Biol Sci, Egham TW20 0EX, Surrey, England
[2] UCL Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England
[3] Duke Univ, Med Ctr, Dept Pediat, Div Genet, Durham, NC 27710 USA
[4] GlaxoSmithKline Inc, Res & Dev, Med Res Ctr, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1093/hmg/11.1.43
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apolipoprotein E (apoE) is a 34 kDa glycoprotein with multiple actions that help protect against the development of atherosclerosis. Here, we have assessed the atheroprotective potential of an [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE, comparing intramuscular and intravenous (liver-directed) injections in hypercholesterolaemic apoE-deficient mice (apoE(-/-)). Intramuscular injections resulted in low expression of apoE and afforded no protection against atherogenesis. In contrast, 3 and 7 days after intravenous injections into young (6-8-week-old) apoE(-/-) mice, plasma levels of apoE were elevated and were accompanied by reductions in plasma cholesterol and normalization of lipoprotein profiles. Thereafter, plasma apoE was still detectable up to day 70, but gradually declined, although no humoral immune response was evoked, and there was a return to dyslipoproteinaemia. High levels of the vector genome were still present in livers of treated animals at 70 days, implying that decrease in apoE expression was due to cellular shutdown of the cytomegalovirus promoter. Importantly, liver-directed apoE gene transfer to these young mice retarded progression of atherosclerosis by 38% (treated, 8.21 +/- 1.05%; untreated, 13.26 +/- 0.98%, P < 0.05), during the 70 day study period. Moreover, when 10-month-old apoE(-/-) mice with advanced atherosclerosis were treated with the adenovirus vector, there was clear regression of aortic lesion area by 1 month [24.3 +/- 1.7% compared to 40.7 +/- 2.6% in baseline controls (P < 0.002)]. We conclude that the stability of the adenovirus vector genome in the livers of intravenously treated animals provides an ideal platform to evaluate liver-specific promoters for sustained transgene expression and control of atherosclerotic lesion pathology.
引用
收藏
页码:43 / 58
页数:16
相关论文
共 68 条
  • [1] Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy
    Amalfitano, A
    Chamberiain, JS
    [J]. GENE THERAPY, 1997, 4 (03) : 258 - 263
  • [2] Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
    Amalfitano, A
    Hauser, MA
    Hu, HM
    Serra, D
    Begy, CR
    Chamberlain, JS
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (02) : 926 - 933
  • [3] Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice
    Athanasopulos, T
    Owen, JS
    Hassall, DG
    Dunckley, MG
    Drew, J
    Goodman, J
    Tagalakis, AD
    Riddell, DR
    Dickson, G
    [J]. HUMAN MOLECULAR GENETICS, 2000, 9 (17) : 2545 - 2551
  • [4] Hybrid female matings are directly related to the availability of Rana lessonae and Rana esculenta males in experimental populations
    Bergen, K
    Semlitsch, RD
    Reyer, HU
    [J]. COPEIA, 1997, (02) : 275 - 283
  • [5] TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA IN APOLIPOPROTEIN E-DEFICIENT MICE BY BONE-MARROW TRANSPLANTATION
    BOISVERT, WA
    SPANGENBERG, J
    CURTISS, LK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) : 1118 - 1124
  • [6] BRESLOW JL, 1982, J BIOL CHEM, V257, P4639
  • [7] CLADARAS C, 1987, J BIOL CHEM, V262, P2310
  • [8] CELLULAR AND HUMORAL IMMUNE-RESPONSES TO ADENOVIRAL VECTORS CONTAINING FACTOR-IX GENE - TOLERIZATION OF FACTOR-IX AND VECTOR ANTIGENS ALLOWS FOR LONG-TERM EXPRESSION
    DAI, YF
    SCHWARZ, EM
    GU, DL
    ZHANG, WW
    SARVETNICK, N
    VERMA, IM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) : 1401 - 1405
  • [9] Production of first generation adenovirus vectors: a review
    Danthinne, X
    Imperiale, MJ
    [J]. GENE THERAPY, 2000, 7 (20) : 1707 - 1714
  • [10] APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS
    DAVIGNON, J
    GREGG, RE
    SING, CF
    [J]. ARTERIOSCLEROSIS, 1988, 8 (01): : 1 - 21